FOXO3 and endometrial cancer: For example, an obesity-associated cancer expression signature was defined in breast cancer [24]; gene microarray data revealed different signatures between obese and nonobese endometrial cancer patients [25]; PTEN loss resulted in PI3K pathway activation in nonobese patients, downregulation of β-CATENIN, and FOXO3A phosphorylation in obese patients in endometrial cancer [26], and DNA methylation pattern of excess body weight patients was changed in breast, colorectal, and kidney cancer [27–29].